MedTrace Logo

Misoprostol Prior to Intrauterine Device (IUD) Insertion in Nulliparous Women

NCT01147497 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2018-01-12

Study results available
· View outcomes & findings →

Summary

Because of misoprostol's known ability to cause cervical dilation, some family planning providers give their patients a dose of this drug prior to insertion. The goal of this study is to evaluate whether misoprostol prior to IUD insertion in nulliparous women eases insertion and decreases pain.

Conditions

  • Contraception

Interventions

DRUG

Misoprostol

400mcg of misoprostol taken buccally 2 hours prior to IUD insertion visit

DRUG

Placebo

Pill that is identical to the study drug in appearance, taste and smell, taken buccally 2 hours prior to IUD insertion visit

Sponsors & Collaborators

  • Emory University

    lead OTHER

Principal Investigators

  • Eva Lathrop, MD, MPH · Emory University School of Medicine, Department of Gynecology and Obstetrics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01147497 on ClinicalTrials.gov